SUMMARY
Probiotics are widely prescribed for prevention of antibiotics-associated dysbiosis and related adverse effects. However, probiotic impact on post-antibiotic reconstitution of the gut mucosal host-microbiome niche remains elusive. We invasively examined the effects of multi-strain probiotics or autologous fecal microbiome transplantation (aFMT) on post-antibiotic reconstitution of the murine and human mucosal microbiome niche. Contrary to homeostasis, antibiotic perturbation enhanced probiotics colonization in the human mucosa but only mildly improved colonization in mice. Compared to spontaneous post-antibiotic recovery, probiotics induced a markedly delayed and persistently incomplete indigenous stool/mucosal microbiome reconstitution and host transcriptome recovery toward homeostatic configuration, while aFMT induced a rapid and near-complete recovery within days of administration. In vitro, Lactobacillus-secreted soluble factors contributed to probiotics-induced microbiome inhibition. Collectively, potential post-antibiotic probiotic benefits may be offset by a compromised gut mucosal recovery, highlighting a need of developing aFMT or personalized probiotic approaches achieving mucosal protection without compromising microbiome recolonization in the antibiotics-perturbed host.
INTRODUCTION
Antibiotics have transformed medicine and the fight against common life-threatening bacterial infections (Van Boeckel et al., 2014) . However, widespread antibiotic exposure is associated with the emergence of resistant strains and with a variety of gastrointestinal (GI) effects, hypersensitivity, and drug-specific adverse effects, most notably antibiotic-associated diarrhea (AAD) in 5% to 35% of treated humans (Wiströ m et al., 2001 , McFarland, 1998 . Non-selective antibiotics-induced disruption of commensal microbiome community structure (''dysbiosis'') accounts for up to 20% of all AAD cases (Bartlett, 2002) . Such dysbiosis occurs rapidly within days, leading to altered bacterial metabolism and impaired host proteome in mice and humans (Ferrer et al., 2014 , Lichtman et al., 2016 . Human microbiome reconstitution from antibiotic treatment is often slow and incomplete (Dethlefsen et al., 2008 , Dethlefsen and Relman, 2011 , Jernberg et al., 2007 and, in some cases, may take years to revert to naive configuration (Lankelma et al., 2017) . Of note, studies in rodent models and humans suggest an association between antibiotic exposure, especially during early stages of life, and a host propensity for a variety of long-term disorders (Vangay et al., 2015) , including obesity (Shao et al., 2017) , allergy (Risnes et al., 2011 , Hoskin-Parr et al., 2013 , increased risk of autoimmunity (Arvonen et al., 2015) , and inflammatory bowel disease (Virta et al., 2012 , Kronman et al., 2012 .
Probiotics have been proposed to constitute an effective preventive treatment for antibiotics-induced dysbiosis and associated adverse effects in mice (Ekmekciu et al., 2017) and in some (Hempel et al., 2012) but not all human studies (Olek et al., 2017 , Allen et al., 2013 . Importantly, adverse effects associated with probiotics consumption may be under-reported in clinical trials (Bafeta et al., 2018) , further complicating the efficacy debate. The extent and pattern of probiotic gut mucosal colonization and impact on the indigenous gut microbiome following antibiotic use also remain unclear. While few smallscale culture-based studies attempted to quantify supplemented probiotics in the antibiotics-perturbed GI mucosa (Klarin et al., 2005) , the vast majority of studies extrapolate their conclusions from stool samples, resulting in inconclusive findings regarding probiotics capability to restore the pre-antibiotics microbiome configuration (McFarland, 2014) . Importantly, no in vivo studies have directly examined the global extent of human mucosal probiotic colonization following antibiotic treatment and their impact on reconstitution of the indigenous mucosal microbiome or the host gut transcriptome.
Here, we explored the impact of probiotics consumption following antibiotic exposure on the gut luminal, mucosal, and fecal microbiome composition and function and the GI transcriptome in mice and humans. To this aim, mice and a cohort of human volunteers were treated with broad-spectrum antibiotics and then either were supplemented with probiotics, underwent autologous fecal microbiome transplantation (aFMT), or were allowed to spontaneously recover over time. We found significant differences between mice and humans with respect to post-antibiotic probiotics gut mucosal colonization. Mice featured only a mild improvement in colonization of the ''human-compatible'' probiotics regimen upon antibiotic treatment as compared to homeostatic conditions, while humans demonstrated a marked colonization improvement in this setting. Importantly, post-antibiotic probiotic supplementation significantly delayed the extent of reconstitution of the indigenous fecal and mucosal microbiome (in both mice and humans) and the reversion of the gut transcriptome toward homeostatic configuration (in humans) compared to either spontaneous reconstitution or aFMT. In contrast, post-antibiotic aFMT in both mice and humans achieved a rapid and near-complete gut mucosal microbiome recolonization associated with reversion of the human gut transcriptome toward its pre-antibiotic configuration.
RESULTS

Experimental Setup in Mice
Under homeostatic conditions , administration of a multi-strain probiotic preparation was associated with limited colonization in mice and with person-specific gut mucosal colonization resistance in humans. To study the postantibiotic mucosal colonization capacity of probiotics and their impact on the indigenous mucosal microbiome as compared to aFMT or watchful waiting, we performed the MUcosal Search for Probiotic Impact and Colonization 3 (MUSPIC3) study in mice and in humans. In mice, we supplemented the drinking water of adult male wild-type (WT) C57BL/6 mice with a broad-spectrum antibiotic regimen of ciprofloxacin and metronidazole for 2 weeks. The immediate impact of antibiotic treatment on gut mucosal microbiome configuration was assessed in one group of mice sacrificed after the 2-week antibiotic exposure (Figure 1A, ''Antibiotics'') . The remaining animals (n = 30) were divided into three post-antibiotic intervention groups. In the first group (''Probiotics''), antibiotic treatment was followed by 4 weeks of daily administration by oral gavage of a commercially prescribed probiotics product involving 11 strains that was validated for composition and viability by multiple methods : Lactobacillus acidophilus (LAC), L. casei (LCA), L. casei sbsp. paracasei (LPA), L. plantarum (LPL), L. rhamnosus (LRH), Bifidobacterium longum (BLO), B. bifidum (BBI), B. breve (BBR), B. longum sbsp. infantis (BIN), Lactococcus lactis (LLA), and Streptococcus thermophilus (STH) . Each mouse of the second group (''aFMT'') received, on the day following cessation of antibiotics, an oral gavage of its own pre-antibiotics stool microbiome. A third group (''Spontaneous'') remained untreated following antibiotic therapy to assess the spontaneous recovery of the indigenous gut microbiome in this setting. An additional group of mice (''Control'') did not receive antibiotics or any other treatment and was followed throughout the study's duration.
Antibiotic Treatment Mildly Enhances Probiotic Gut Mucosal Colonization in Mice
We first assessed the fecal and mucosal colonization of probiotics following broad-spectrum antibiotic treatment in mice. 16S rDNA indicated that three of the four genera comprising the probiotics mix (Lactobacillus, Bifidobacterium, and Streptococcus) were present in stool samples even prior to antibiotic administration (Figures S1A-S1C). 1 day following probiotics administration, Lactobacillus (Figure S1A) , Bifidobacterium (Figure S1B) , and Lactococcus genera ( Figure S1D ) increased in relative abundance (RA). On day 4, only Bifidobacterium RA remained elevated, after which none of the genera RAs were significantly higher in the treated group ( Figures S1A-S1D ). Given the inability of 16S rDNA analysis to distinguish absolute abundance changes at the species level, we utilized a sensitive species-specific qPCR ) targeting each of the tested 11-probiotic species. A pooled qPCR analysis for all species in stool indicated >10,000-fold fecal enrichment of probiotic species on days 1 and 4 of probiotic supplementation (Figure 1B) , which rapidly declined in the following days, thereby losing statistical significance, though the trend persisted throughout the experiment (incremental area under the curve [iAUC] p < 0.0001 versus each group). A per-species analysis indicated 9 of the 11 species (all but BBI and LAC) to be significantly enriched in stool during probiotics supplementation (Figure 1C) .
Like in stool, 16S rDNA assessment of mucosal gut surfaces did not detect a significant elevation in the RA of any of the probiotics genera in any of the regions (Figures S1E-S1H). A pooled qPCR analysis for all administered probiotic species indicated significantly higher abundance in the lumen of the lower GI (LGI), but not the LGI mucosa ( Figure 1D ) or the upper GI (UGI; Figure 1E ). The species that were significantly elevated in the lumen of the LGI tissues and the stomach were consistent with those shed in stool, while only BBR, LRH, and STH were significantly elevated in the LGI mucosa ( Figure 1F ). In comparison, mice that received probiotics using the same experimental design but without antibiotics pre-treatment featured a significantly lower aggregated probiotics load of all targets in the GI lumen, but not the mucosa ( Figure S2A ). These results indicate that resistance to the presence of probiotic species in the murine Four groups of WT mice (n = 10) were treated for 14 days with ciprofloxacin and metronidazole in drinking water, after which one group was immediately dissected and three others were followed by either daily probiotics administration, a single aFMT with a pre-antibiotics fecal sample, or no intervention (spontaneous recovery). A fifth group (n = 10) did not receive antibiotics and remained untreated throughout. Absolute abundances of probiotics species were determined by qPCR in fecal samples collected at the various experimental stages or in GI tract tissues 28 days post antibiotics. (A) Experimental design. (B) qPCR-based fold change of pooled probiotics targets in fecal samples normalized to baseline (before antibiotics). ****p < 0.0001; two-way ANOVA and Tukey. Inset: incremental area under the curve describing the fold difference in cycle threshold (ddCT) between an indicated time-point and baseline, calculated from day 0 post antibiotics. ****p < 0.0001; Kruskal-Wallis and Dunn's. (C) Same as (B) but for each probiotics species separately without normalization. *p < 0.05, two-way ANOVA and Dunnett. (D and E) qPCR-based enumeration of pooled probiotics targets in tissues of the (D) LGI or (E) UGI. **p < 0.01, ****p < 0.0001; Kruskal-Wallis and Dunn's. (F) Same as (D) and (E) but for each probiotics species separately. *p < 0.05; two-way ANOVA and Dunnett. Symbols represent the mean, error bars represent SEM. ST, stomach; DU, duodenum; PJ, proximal jejunum; DJ, distal jejunum; IL, ileum; CE, cecum; PC, proximal colon; DC, distal colon; Ctrl, control; Abx, antibiotics; Sp, spontaneous recovery; Prob, probiotics; BBI, Bifidobacterium bifidum; BBR, Bifidobacterium breve; BIN, Bifidobacterium longum subsp. infantis; BLO, Bifidobacterium longum; LAC, Lactobacillus acidophilus; LCA, Lactobacillus casei; LLA, Lactococcus lactis; LPA, Lactobacillus casei subsp. paracasei; LPL, Lactobacillus plantarum; LRH, Lactobacillus rhamnosus; STH, Streptococcus thermophilus. The experiment was repeated three times. See also Figure S1 . 16S rDNA-based comparison of post ciprofloxacin and metronidazole reconstitution in probiotics-treated mice (n = 10) compared to mice treated with aFMT (n = 10) and mice that did not receive post-antibiotics treatment and were followed up for 28 days (n = 10) or sacrificed immediately after antibiotics (n = 10) and no antibiotics controls (n = 10). (A) Alpha diversity quantified as observed species in fecal samples. *p < 0.05, ****p < 0.0001 between probiotics and each of the other groups; two-way ANOVA and Dunnett. (B) Unweighted UniFrac distances to baseline in feces. ****p < 0.0001 between probiotics and each of the other groups; two-way ANOVA and Dunnett. (C) Genera significantly (false discovery rate [FDR]-corrected p < 0.05; Mann-Whitney) reduced by antibiotics in feces, which returned to baseline levels in aFMT and spontaneous recovery, but not in probiotics. In square brackets, the lowest taxonomic rank for which information was available; O, order; F, family; G, genus. (D) Relative abundance of Blautia in fecal samples. ****p < 0.0001; two-way ANOVA and Dunnett. GI lumen is contributed by the resident microbiome. This resistance is partially alleviated by antibiotics, although even after antibiotics pre-treatment, the tested probiotics demonstrated mild and sporadic mucosal presence, potentially reflecting lower colonization capacity of these human-compatible probiotics species in the murine gut mucosa.
Probiotics Delay and aFMT Improves the Post-Antibiotic Reconstitution of the Indigenous Murine Microbiome We next determined the impact of the probiotic formulation on reconstitution of the indigenous murine fecal and mucosal gut microbiome community following antibiotic treatment. Expectedly, antibiotic treatment resulted in a dramatic reduction in stool alpha diversity (>66% reduction; Figure 2A ) and general disruption of the fecal bacterial community structure as evident by unweighted UniFrac distances to baseline (Figure 2B) . Of the three post-antibiotic interventions, aFMT was most efficient in restoring fecal bacterial richness to that observed in the control, with alpha diversity becoming indistinguishable to control within 8 days following aFMT (p = 0.11). In contrast, both probiotics and spontaneous recovery did not restore fecal alpha diversity to baseline levels 4 weeks following antibiotic cessation. Importantly, probiotics significantly delayed the return to baseline microbiome richness even compared to spontaneous recovery as evident in all tested time points (Figure 2A ).
Delayed murine probiotics-induced microbiome reconstitution was also reflected in the kinetics of return to pre-antibiotics baseline fecal composition as expressed by UniFrac distances. Expectedly, all treatment groups were dramatically shifted from baseline stool composition upon antibiotic treatment. While aFMT returned to baseline by day 28 after antibiotic treatment (p = 0.83; Figure 2B ), both the probiotics and spontaneous recovery groups failed to fully return to baseline within 4 weeks of antibiotics cessation, with microbiome in the probioticsadministered group featuring the slowest recovery rate (p = 0.0001). As a greater distance to baseline in the probioticssupplemented group may be merely a result of new exogenous bacteria introduced into the microbiome, we repeated the measurement after removing the four probiotics genera from the analysis and renormalizing RAs to 1 and corroborated the greater distance to baseline of the probiotics-supplemented group, reflecting an impaired indigenous mucosal microbiome reconstitution in this group (Figure S2B) . A pairwise comparison of fecal microbial composition between the last day of follow-up and baseline demonstrated 28 taxa significantly differentially represented in the probiotics group ( Figure S2C ) with a >10-fold increase in the abundance of Blautia and no significant increase in any of the probiotics genera. Fewer significant differences were observed in the spontaneous recovery (16 taxa; Figure S2D ) and aFMT (6 taxa; Figure S2E ) groups. Of all taxa significantly reduced by antibiotics, 13 taxa belonging to 4 different phyla returned to baseline levels in both the aFMT and spontaneous recovery groups, but not in the probiotics group ( Figure 2C ). In contrast, five taxa were over-represented in the stool samples of the probiotics and significantly inversely correlated with alpha diversity: Akkermansia, Vagococcus, Enterococcus, Blautia, and Lactococcus. Of these, only Blautia bloomed exclusively in the probiotics group after antibiotics cessation ( Figure 2D ). Interestingly, macroscopic differences were noted between the ceca of probiotics-administered and spontaneously recovering mice, with the former being larger (representatives in Figure S2F ) and significantly heavier (Figure S2G) , reminiscent of germ-free mice or mice treated with broad-spectrum antibiotics.
Consistent with the findings in stool, the number of observed species in the probiotics group was comparable to the group dissected immediately after 2 weeks of antibiotics and significantly lower compared to the control, aFMT, and spontaneous recovery groups in both the lumen and the mucosa of the LGI ( Figure 2E ) and UGI (Figure 2F) . No significant differences were noted between the aFMT and control groups in any of the regions, whereas the richness in the spontaneous group was in between that of aFMT and probiotics ( Figures 2E and 2F ). Reduced alpha diversity in the LGI of the probiotics group was at least partly due to a total reduction in LGI bacterial load (Figure 2G) . In agreement, the UniFrac distance to control of the mucosal and luminal aFMT microbiome configuration was lower than that of the spontaneously recovering group, with the largest distance to control featured by the probiotics-administered group . As in stool, these colonization differences could not be explained by the mere presence of probiotics genera in probiotics-administered mice, as the result remained unchanged even if probiotics genera were excluded from the analysis ( Figures S2I and S2J) . Interestingly, microbiome composition of aFMT-treated mice was indistinguishable from controls both in the LGI and the UGI, suggesting that fecal microbiome was sufficient to recapitulate the distinct UGI microbiome ( Figure S2H ). Of the taxa significantly reduced in the LGI mucosa of the antibiotics group compared to control, 16 returned to control levels in both the aFMT and the spontaneous recovery groups, but not in the probiotics group, of which 11 belonged to the Clostridiales order; two genera (Blautia and Streptococcus) significantly bloomed exclusively in the probiotics group (Figure 2J) . Four taxa predominant in the probiotics group had a high (Spearman r < À0.6) and significant (p < 0.0001) inverse correlation with the alpha diversity in the LGI mucosa:
Vagococcus, Akkermansia muciniphila, Blautia producta, and Enterococcus casseliflavus ( Figure S2K ). These blooming taxa may thus play a role in probiotics-induced inhibition of microbiome reconstitution.
(E and F) Alpha diversity in tissues of the (E) LGI or (F) UGI. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; N.S., not significant; Kruskal-Wallis and Dunn's. To ascertain that the delayed return to homeostatic indigenous microbiome configuration following probiotics treatment was not a unique feature of the studied vivarium, we performed the same set of interventions in mice housed in a different specific-pathogen-free (SPF) animal facility with distinct baseline fecal microbiome (26 taxa significantly differentially represented; Figure S3A ). In this vivarium as well, aFMT induced a rapid indigenous microbiome post-antibiotic reconstitution as compared to watchful waiting, while the 11-strain probiotic treatment delayed the speed and magnitude of the recolonization process ( Figures S3B-S3K) .
Collectively, 4 weeks of spontaneous recovery following a broad-spectrum antibiotic treatment in mice partially restored baseline gut mucosal configuration and bacterial richness and load. Watchful waiting was superior-in its rate of induction of indigenous microbiome reconstitution-to consumption of probiotics, which demonstrated little improvement of the post-antibiotics microbiome configuration and delayed the restoration of homeostatic composition and richness of the pre-antibiotic gut mucosal microbiome. In comparison to both watchful waiting and probiotics administration, aFMT constituted the most efficient treatment modality, enabling rapid restoration of both upper-and lower-gut mucosal microbiome to homeostatic configuration following antibiotic treatment in mice.
Human Experimental Design
We next set out to determine how the 11-strain probiotics or aFMT would affect the post-antibiotic human luminal and mucosa-associated microbiome reconstitution. To this aim, we conducted a prospective longitudinal interventional study in 21 healthy human volunteers not consuming probiotics (Table S1 and STAR Methods) who were given an oral broad-spectrum antibiotic treatment of ciprofloxacin and metronidazole at standard dosages for a period of 7 days (Figure 3A) . Following antibiotic treatment, seven participants were followed by watchful waiting for spontaneous microbiome reconstitution, six participants received aFMT (STAR Methods), and eight participants received the aforementioned 11-strain probiotics preparation administered bi-daily for a period of 4 weeks ( Figure 3A ). Endoscopic examinations were performed twice in each of the 21 participants. A first colonoscopy and deep endoscopy were performed after completion of the week-long antibiotic course, thereby characterizing the post-antibiotics dysbiosis throughout the GI tract. A second colonoscopy and deep endoscopy were performed 3 weeks later (day 21) to assess the degree of gut mucosal and luminal reconstitution in each of the three treatment arms ( Figure 3A ). Multiple stool samples were collected at intervals indicated in Figure 3A up to 6 months from antibiotics cessation. In total, 337 luminal, 702 mucosal, and 557 stool samples, as well as 362 regional biopsies, were collected.
Probiotics in Antibiotics-Perturbed Humans Are Continuously Shed in Stool and Colonize the LGI Mucosa
Expectedly, antibiotic treatment in humans triggered a profound fecal microbial depletion ( Figure S4A ) and disruption of microbial community composition ( Figure S4B ) as observed in stool (Figures S4C and S4D) , LGI mucosa (Figures S4E and S4F) , and UGI mucosa (Figure S4G) , with the latter region the least affected by antibiotics ( Figure S4H ). Compositional changes were accompanied by alteration of microbiome function in the stool and LGI as assessed by shotgun metagenomic sequencing .
Fecal 16S rDNA analysis demonstrated that all probioticsrelated genera were found in stools prior to probiotics supplementation, and Lactobacillus, Lactococcus, and Streptococcus significantly expanded in RA following antibiotics treatment. All four probiotics genera remained significantly elevated compared to baseline during probiotics supplementation, though none were further elevated to the post-antibiotics levels. Following cessation of probiotic treatment, none of the genera remained significantly elevated compared to baseline ( Figures S5A-S5D ).
A fecal species-level metagenomic analysis (MetaPhlAn2) also demonstrated an antibiotics-induced expansion in RA of 6 of 11 species compared to baseline (BBI, BBR, BLO, LAC, LLA, and STH; Figure S5E ), while during probiotic treatment, all species expanded compared to baseline, but only BBI and BLO reached statistical significance with this method ( Figure S5E ). A shotgun metagenomic sequencing strain-specific method (Sharon et al., 2013) identified one of the probiotic strains in a single baseline day in stool, two of the probiotics strains (different than the one appearing at baseline) during antibiotic treatment, and six of the pill-specific strains (BBI, BBR, BLO, LLA, LPL, and LRH) in multiple days during probiotics exposure. BBI, BLO, and BBR were also shed after cessation by the same participants ( Figure 3B ).
Fecal species-specific qPCR, the most sensitive method, revealed a significant fecal expansion during probiotics administration of the 11-probiotic species when considered together, with 7 of 11 species being significantly elevated from baseline when analyzed separately during consumption (BBR, BIN, LAC, LCA, LLA, LPL, and LRH; Figure 3C ). This probiotic-species expansion was significant compared to both aFMT and spontaneous recovery (Figures 3D and S5F) . Even 5 months after probiotics cessation, several probiotics species remained elevated in stools of the probiotics-supplemented group compared to baseline ( Figures 3D and S5F ).
Given the above continuous shedding in stool, we assumed that the post-antibiotic gut mucosal colonization of probiotics is also enhanced as compared to that observed during homeostasis . 16S rDNA analysis of luminal and mucosal GI samples collected before and after 3 weeks of probiotics indicated no significant increases in the RA of probiotic genera in the GI lumen (Figure S5G) or mucosa ( Figure S5H ). MetaPhlAn2 analysis indicated that all probiotics species, except LPA, trended toward luminal expansion in RA from baseline, though none reached statistical significance ( Figure S5I ). In contrast, the mucosa of the TI and all LGI regions, except the rectum, featured significantly enhanced levels of probiotics species, stemming mostly from an elevation in BBI and BLO (Figure S5J) . Consequently, improved post-antibiotic probiotics colonization was noted as compared to the naive probioticssupplemented group (p < 0.0001; Figure 3E ). Mucosal speciesspecific qPCR indicated a significant probiotics colonization of the gastric fundus; terminal ileum; ascending, transverse, and sigmoid colon; and the rectum ( Figure 3F ). Probiotics species were also significantly elevated in the ascending and transverse colon of the post-antibiotics spontaneous recovery group, while Three groups of humans were treated for 7 days with ciprofloxacin and metronidazole followed by either bi-daily probiotics pill administration (n = 8), aFMT of stool obtained before the antibiotics intervention (n = 6), or no intervention (spontaneous recovery; n = 7). Two endoscopic procedures were performed, and multiple stool samples were collected throughout the trial. (A) Outline of the three arms of intervention in humans. (B) Probiotics strain quantification in stool based on mapping of metagenomic sequences to unique genes that correspond to the strains found in the probiotics pill. Dark gray marks the presence of the probiotics species, and red marks the presence of the probiotics strains. (C) qPCR quantification of probiotics species in stools from last day of antibiotics (Abx) , day 19 of probiotics supplementation (Prob) , and 1-5 months after cessation normalized to samples from the last baseline day before antibiotics. *p < 0.05; two-way ANOVA and Dunnett. (D) Aggregated Probiotics load in stool in the three groups from the last day of antibiotics until 5 months of follow-up. SSS and FFF denote p < 0.001 versus spontaneous recovery or aFMT, respectively; two-way ANOVA and Tukey. Inset: iAUC from each group's baseline. ****p < 0.0001; Kruskal-Wallis and Dunn's. (E) MetaPhlAn2-based aggregated quantification of probiotics species expansion (day 21 normalized to baseline) in tissues of individuals pre-treated with antibiotics or antibiotics-naive . ****p < 0.0001; Mann-Whitney. (F) qPCR-based fold changes of probiotics species abundance in each mucosal tissue of each group. *p value < 0.05; two-way ANOVA for tissues and Dunnett per species per tissue relative to baseline. (G) qPCR-based aggregated fold change in probiotics species abundance. ***p < 0.001, ****p < 0.0001; Kruskal-Wallis and Dunn's. Symbols represent the mean; error bars represent SEM. GF, gastric fundus; GA, gastric antrum; Du, duodenum; Je, jejunum; TI, terminal ileum; Ce, cecum; AC, ascending colon; TC, transverse colon; DC, descending colon; SC, sigmoid colon; Re, rectum. (legend continued on next page) no significant elevation was observed in the aFMT group (Figure 3F ). On average, probiotics species expanded 8.7-fold more in the probiotics-supplemented group compared to spontaneous (p = 0.0001) and 53.9-fold compared to aFMT (p < 0.0001; Figure 3G ).
To determine whether antibiotics-treated individuals feature a person-specific colonization permissiveness/resistance to probiotics, similar to our observations under homeostatic conditions , we calculated qPCR-based individual fold changes in the probiotic load between the first and last days of probiotics supplementation ( Figure S6A ). In four participants, a significant >100-fold increase in mucosal probiotics load (aggregated for all targets) was observed (Wilcoxon p < 0.02). A fifth participant featured a milder but significant elevation. Three additional participants experienced a non-significant trend toward probiotics mucosal expansion. A probiotic-strain-specific shotgun-based validation analysis reflected this individualized pattern observed by qPCR and indicated that the colonizing strains originated from the supplemented pill ( Figure S6B ). The etiology and impact of these apparent inter-individual differences in post-antibiotic probiotic colonization merit further studies in larger cohorts.
Collectively in the antibiotics-perturbed human gut, reversal of colonization resistance to probiotics enabled incremental gut colonization by the tested exogenously administered probiotic strains, mainly in the large intestine, leading to long-term probiotic fecal shedding indicative of stable colonization and active proliferation. Probiotic species belonging to Bifidobacterium were colonized at higher levels compared to the other tested probiotics species.
Probiotics Delay While aFMT Improves the PostAntibiotic Reconstitution of the Indigenous Human Fecal Microbiome We next assessed the contribution of the three post-antibiotic treatment arms to reconstitution of the indigenous fecal microbiome in humans. We first utilized fecal MetaPhlAn2 speciesbased analysis to calculate the Bray-Curtis dissimilarity indices between stools collected during antibiotics treatment or during the reconstitution period to that of baseline stool microbiome configuration ( Figures 4A and 4B ). Of note, dissimilarity from baseline more than tripled during antibiotics treatment in all groups, reflecting the dramatic impact of antibiotics on stool microbiome configuration. aFMT-treated individuals were quickest to return to baseline configuration, with differences in stool composition compared to baseline disappearing as early as 1 day following aFMT (Figure 4B ). In the spontaneous recovery group, significant differences in stool composition compared to baseline abated within 21 days of antibiotics cessation (Figure 4B) . In contrast, probiotics-consuming individuals did not return to their baseline stool microbiome configuration by the end of the intervention period (day 28), and dysbiosis was maintained even 5 months after probiotics cessation, with all stool samples collected through day 180 remaining significantly different from baseline (two-way ANOVA and Dunnett p < 0.01; Figures 4A  and 4B ). In addition to differences from baseline, probioticsconsuming individuals were also significantly distinct from the spontaneous recovery group through days 7-28 of the reconstitution. Consequently, the area under the probiotics-administered group reconstitution curve was significantly higher than aFMT and spontaneous recovery ( Figure 4B ). As in mice, the distinct microbiome composition could not be explained by the mere presence of probiotics species in probiotics-consuming individuals, as the result remained unchanged even if probiotics species were excluded from the analysis and RAs were renormalized ( Figures S6C and S6D ). Delayed reconstitution in probiotics-consuming individuals was also observed by 16S-rDNA-based unweighted UniFrac distances ( Figures 4C and  4D ) even when probiotics genera were omitted from the analysis ( Figures S6E and S6F) .
We next quantified species and functional KEGG orthologs (KOs) that were more than 2-fold distinct in their fecal abundances between baseline (pre-antibiotics) and the end of reconstitution in the three arms. aFMT featured the fewest number of fecal species distinct between baseline and endpoint (29 species; Figure S6G ), while probiotics had the most fecal species distinct between baseline and endpoint (96; Figure S6H )-almost double than those observed during spontaneous recovery (51; Figure S6I ). Three taxa significantly reverted to naive levels by aFMT, but not by spontaneous recovery (Alistipes shahii, Roseburia intestinalis, and Coprococcus). Microbiome function, as determined by fecal KOs, displayed the same (B) Bray-Curtis dissimilarity to baseline stool samples of each participant (mean of a group is plotted) throughout the experiment. Colored asterisks indicate any p < 0.05 versus baseline for clarity; two-way ANOVA and Dunnett. Inset: area under the post-antibiotics reconstitution curve for each group. *p < 0.05; KruskalWallis and Dunn's. pattern (9 KOs in aFMT, 123 in probiotics, and 17 in spontaneous recovery; Figures S6J-S6L, respectively) . Importantly, following antibiotics treatment, the number of observed species in feces was halved but was restored in both the aFMT and the spontaneous recovery groups within 1 and 2 days, respectively (Figure 4E) . In contrast, the alpha diversity remained significantly low and did not return to baseline in the probiotics group throughout the intervention period (two-way ANOVA and Dunnett p < 0.05; Figure 4E ), with the alpha diversity reconstitution curve remaining lower compared to its own baseline, as well as aFMT or spontaneous, up to 5 months post probiotics cessation ( Figure 4E ). Likewise, fecal bacterial load failed to return to baseline after 3 weeks of probiotics supplementation, as compared to both aFMT and spontaneous recovery (Figure 4F) , and remained lower than baseline 1 month after probiotics supplementation ceased.
Of the species altered in fecal RA by antibiotics, we identified 20 that returned to baseline levels in the aFMT and spontaneous recovery groups, but not in the probiotics group ( Figure 4G ). As in the mouse, the majority of the probiotics-inhibited species belonged to the Clostridiales order. A comparison between the probiotic-induced taxonomic changes in humans and mice indicated that four taxa-Enterococcus, Akkermansia, Bifidobacterium, and Blautia-bloomed after probiotics supplementation in both species ( Figure 4H ). To assess which of the blooming taxa may be involved in microbiome inhibition, we correlated 16S-and MetaPhlAn2-based abundances with alpha diversity. 14 genera and 107 species were significantly inversely correlated with alpha diversity, including the majority of probiotics species (excluding LPA and STH), as well as E. casseliflavus and B. producta that were also significantly inversely correlated with alpha diversity in the mouse LGI mucosa (Figures 4I and  S2K and Table S2 ). Likewise, we identified multiple pathways that returned to their pre-antibiotics state in aFMT and spontaneous recovery, but not in probiotics ( Figure 4J ). 37 KOs and 60 pathways, the majority of which relate to metabolism, were significantly inversely correlated with alpha diversity in stool (Table S2 ). The highest anti-correlation was with galactose metabolism, which, along with additional pathways, may be related to lactate production and consequently microbiome inhibition by the probiotic species that bloom in the fecal samples ( Figure 4K) .
Together, while probiotics species colonized the mucosa of the antibiotics-perturbed human gut, they delayed the stool microbiome compositional, functional, and diversity-related reconstitution toward a pre-antibiotic configuration. This delayed fecal reconstitution persisted even 5 months after probiotic cessation. In contrast, aFMT induced a rapid and nearly complete fecal microbiome reconstitution as compared to either the watchful waiting or probiotics-administered groups.
Probiotics Delay the Post-Antibiotic Reconstitution of the Indigenous Human Mucosal Microbiome We next assessed whether the above inverse probiotics-and aFMT-induced impacts on stool microbiome reconstitution could be documented at the gut mucosa level. We focused on the LGI, given the preferential probiotic post-antibiotic colonization at this region ( Figures 3G and S5I and S5J ). Both 16S-rDNA ( Figures 5A and 5B ) and MetaPhlAn2-based ( Figures 5C and 5D ) analyses demonstrated that the aFMT and spontaneous recovery LGI luminal and mucosal configurations were significantly more similar to that of naive non-antibiotics-treated controls than to the antibiotics-perturbed configuration. In contrast, the probiotics LGI configuration remained similar to the antibioticsperturbed configuration ( Figures 5A-5D ). The greater distance from the naive configuration of the probiotics group was not merely reflecting the presence of the probiotics species, as removal of the probiotics genera ( Figures S7A and S7B ) or species ( Figures S7C and S7D ) from the distance analysis maintained the aforementioned pattern. The function of the microbiome in KOs ( Figures 5E and 5F ) and pathways ( Figures S7E  and S7F ) also mirrored the delayed probiotics-associated restoration of the indigenous mucosal LGI microbiome. As in stool, the LGI mucosa of the probiotics group displayed a lower alpha diversity, which was comparable to that observed immediately after antibiotics ( Figure 5G ) and reflected also in LGI mucosa bacterial load ( Figure 5H ). As in stool, multiple species ( Figure 5I ) and microbial pathways ( Figure 5J ) were altered by antibiotics and reverted to homeostatic levels by aFMT and spontaneous recovery, but not by probiotics, with all the inhibited species belonging to Clostridiales ( Figure 5I ). 8 genera, 62 species, 80 KOs, and 26 pathways were significantly anti-correlated with alpha diversity in the LGI mucosa, with high similarity in species (69%) and pathways (84%) between stool and mucosa (Table S2) .
Collectively, enhanced post-antibiotic probiotics colonization in the LGI mucosa was associated with a compositional and functional persistence of post-antibiotic dysbiosis reflected in both stool and LGI lumen and mucosa. This delayed return of the indigenous gut microbiome toward pre-antibiotic microbiome composition and function is in line with our observations in mice (Figures 2, S2 , and S3), suggestive of a global mechanism of interaction between the indigenous microbiome and exogenous probiotics across host species. 
(legend continued on next page)
Reversion of Antibiotics-Associated GI Transcriptomic Landscape Is Delayed by Probiotics Given the differential impact of probiotics and aFMT, as compared to watchful waiting, on the recovery of mucosal gut microbiome composition and function, we next sought to characterize the effect of the three post-antibiotics interventions on the host. To this aim, we performed a global gene expression analysis through RNA sequencing of transcripts collected from stomach, duodenum, jejunum, terminal ileum, cecum, and descending colon biopsies immediately after antibiotics treatment and 3 weeks later into the three post-antibiotic interventions (Figure 3A) . Of note, antibiotics affected the transcriptional landscape across the GI tract, with the majority of differences between naive and antibiotics state observed in the descending colon ( Figure 6A ). Importantly, restoration of the antibiotics-naive host transcriptional landscape by the three post-antibiotics intervention arms mirrored our findings in the microbiome, as multiple genes across the GI tract that were significantly affected by antibiotics were reverted toward homeostatic expression levels by spontaneous recovery and aFMT, but not by probiotics ( Figure 6B ). When compared to the global naive (non-antibioticsexposed) transcriptional state, duodenal transcriptomes of the post-aFMT group featured the least amount of significantly differentially expressed genes ( Figure 6C ), followed by the spontaneous recovery group (Figure 6D ), while the duodenal transcriptional landscape was most distinct from the naive state in the probiotics group ( Figure 6E ). In agreement, jejuna from the probiotic groups featured the greatest similarity to the post-antibiotic transcriptional state as compared to the transcriptome of the aFMT or spontaneous recovery groups ( Figures 6F-6H) . The highest number of significant differences between the probiotics and spontaneous recovery groups was observed in the duodenum, including multiple genes belonging to the interferoninduced proteins (IFIs) that were under-expressed in probiotic consumers ( Figure 6I ). Interestingly, probiotics led to an elevation in the transcript levels of inflammatory mediators and regulators of anti-microbial peptide secretion, such as IL1B (Figure 6J) , and of some anti-microbial peptides, such as REG3G (Figure 6K ), potentially contributing to the inhibition of indigenous commensal such as Clostridiales.
Probiotics-Secreted Molecules Inhibit Human Microbiome In Vitro Growth
Finally, we explored potential direct probiotic-mediated mechanisms contributing to the inhibition of indigenous microbiome restoration. To this aim, we utilized a host-free, contact-independent system of probiotics-human-microbiome culture. We began by culturing the probiotics pill content in five selectively enriching growth media, differentially supporting the growth of each of the four genera composing the probiotics consortium ( Figure 7A ). Following 24 hr of anaerobic culture, supernatants from each of the five growth conditions were added to a lag-phase culture of fresh naive human fecal microbiome under anaerobic conditions. Optical density (OD) of the microbiome culture, measured after 8 hr, indicated that soluble factors in the de Man, Rogosa, and Sharpe medium (MRS)-probiotics culture supernatant (which mostly supports the growth of Lactobacillus) inhibited the growth of the naive human microbiome ( Figure 7B ). This inhibitory effect was not merely due to acid production by the probiotic bacteria, as the probiotics filtrate had an additive inhibitory effect to that of a comparably acidified, non-bacterial-exposed medium (pH 4; Figure 7C ). To corroborate that Lactobacillus was indeed the microbiome-inhibitory probiotic, we collected supernatants from (1) an MRS anaerobic culture supernatant of a probiotic pill content, (2) an MRS anaerobic culture supernatant of a mix of the five Lactobacillus species present in the pill, and (3) a non-cultured MRS medium acidified to the levels measured with the other two cultures (pH 4; Figure 7D ). The three supernatants were then cultured with a naive human microbiome under anaerobic conditions. Importantly, a significant growth inhibition was induced by both probiotics and Lactobacillus supernatants as compared to acidified MRS, suggestive of secreted Lactobacillus factors promoting the inhibitory effects ( Figure 7D ). 16S rDNA analysis of the filtrate-supplemented human microbiome cultures following 11 hr of culturing indicated that these soluble factors significantly reduced the number of observed species ( Figure 7E ) and modulated community structure ( Figures 7F and 7G ). This resulted in reduced levels of Prevotella and several taxa belonging to Clostridiales (Figure 7H ), in line with our observations with in vivo probiotic administration.
DISCUSSION
In this study, we examined in both mice and humans the effects of post-antibiotic consumption of an 11-species probiotic preparation or of aFMT on gut mucosal microbiome community structure. We utilized an invasive post-antibiotic endoscopic characterization of the gut mucosa and demonstrated that the homeostatic microbiome-mediated colonization resistance to the administered probiotics is at least partially overcome upon antibiotics treatment, resulting in an improved probiotics colonization of the depleted gut mucosal layer at its entirety-in humans more than in mice. Importantly, in both mice and humans, we demonstrate that enhanced post-antibiotic probiotic colonization comes at a tradeoff of delayed indigenous microbiome and host mucosal transcriptome reconstitution to a homeostatic configuration as compared to either watchful waiting or aFMT. In contrast, aFMT results in rapid and nearly complete reconstitution of the gut mucosal microbiome configuration and host gut transcriptome.
Our study highlights several important points. First, it provides direct evidence that colonization resistance to the administered probiotics in mice, and the person-specific colonization resistance to the administered probiotics in humans , were contributed by the indigenous gut microbiome. In inbred mice featuring a relatively uniform microbiome (J) Normalized number of transcripts for IL1B in the descending colon after 3 weeks reconstitution. (K) Same as (J) but for REG3G in the ileum. St, stomach; Du, duodenum; Je, jejunum; TI, terminal ileum; Ce, cecum; DC, descending colon. *p < 0.05, **p < 0.01; Kruskal-Wallis and Dunn's. Prob, probiotics, Spont, spontaneous recovery. Horizontal lines represent the mean; error bars represent SEM.
configuration, the absence of a microbiome under extreme germ-free condition resulted in preferential and sustained probiotic colonization, pointing toward the indigenous microbiome as a major driver of colonization resistance to these administered strains in the murine gut environment. Less extreme microbiome depletion by broad-spectrum antibiotic treatment in mice only mildly improved probiotics colonization, suggesting that human compatibility of the examined probiotic strains, or other uneradicated microbial factors, may contribute to murine colonization resistance in this setting, in line with a previous report (Grazul et al., 2016) . Humans, in contrast, feature highly diverse microbiome configurations (Yatsunenko et al., 2012 , Zeevi et al., 2015 , driving an individualized capacity of homeostatic colonization of the 11 probiotic strains The content of a probiotics pill was cultured in various media to enhance differential growth. The supernatant was filtered using a 0.22-uM filter and added to a lagphase human fecal microbiome culture in BHI, and growth was quantified by optical density. ( Maldonado-Gó mez et al., 2016 , Goossens et al., 2006 . Antibiotic perturbation in humans, followed by administration of the 11 human-compatible probiotic strains, resulted in a marked mucosal colonization enhancement. Even then, only Bifidobacterium strains persisted following probiotics cessation in some of the individuals-an observation previously suggested to stem from adaptations of the genus to the human gut (Maldonado-Gó mez et al., 2016) . Deciphering the microbial contributors and associated molecular mechanisms orchestrating colonization resistance to exogenous bacteria present during homeostasis and lost during antibiotic treatment may enable harnessing these mechanisms toward better long-term colonization efficacy of probiotics treatment in different clinical contexts.
Second, our study highlights an important previously unappreciated tradeoff in which improved probiotic gut mucosal colonization under disruptive antibiotic conditions led to a markedly delayed indigenous gut mucosal reconstitution in terms of composition, function and bacterial load, and prolonged dysbiosis that lasted at least 5 months following the cessation of probiotic exposure. While our study is not aimed or powered to assess the effectiveness, or lack thereof, of probiotics in ameliorating post-antibiotics clinical symptoms, we demonstrate that their putative ''placeholder'' effect may come at a price of significant prolongation of dysbiosis and delayed recolonization of the indigenous microbiome, resulting in altered reversion of the host gut transcriptome toward homeostatic configuration. This probiotic-induced ''adverse effect'' may be important in light of multiple observations linking antibiotics-associated dysbiosis and lower microbial diversity with increased susceptibility to a myriad of chronic and infectious diseases (Vangay et al., 2015) . The duration, extent, and long-term health consequences of probiotics-induced delayed endogenous microbiome and host transcriptome reconstitution-and whether they occur with other probiotics not tested in our study-merit further studies.
Given this probiotics effect, it would be critically important to further elucidate probiotics-induced factors contributing to the inhibition of indigenous microbiome reconstitution. Synthesis of our human, mouse, and in vitro data points to an antagonistic activity of some probiotics species and related blooming lactic acid bacteria such as Enterococcus and Vagococcus, as well as B. producta and Actinomyces odontolyticus, against the native commensal microbiome, potentially mediated by their previously established anti-microbial activity (Caballero et al., 2017 , Franz et al., 2007 , Cotter et al., 2013 , Franker et al., 1977 that was overlooked in the context of commensals. Genetic or pharmacologic inhibition of such factors may promote better post-probiotic microbiome recovery, thereby complementing probiotics use.
Third, our study highlights the potential advantage of aFMT as an effective means of minimizing the post-antibiotics gut mucosal microbiome ''nadir'' period. Indeed, aFMT, constituting an inherently compatible personalized stool microbiome configuration, was associated with a markedly improved rate of indigenous microbiome colonization and reversion of the host gut transcriptome toward a homeostatic configuration as compared to the tested probiotic preparation or watchful waiting. As such, aFMT may provide a rapid post-antibiotic protection from pathogen and pathobiont engagement with the host during the critical and vulnerable post-antibiotic period without exposing the host to a delayed indigenous microbiome recolonization and its potential long-term consequences. Of note, while aFMT is increasingly studied in various clinical contexts (Kootte et al., 2017) and promoted through non-medical channels and bio-banking entities (Smith et al., 2014 , Terveer et al., 2017 , we expect its widespread use as an ''antibiotics adjuvant'' to be technically challenging, as it necessitates long-term stool storage, extensive pill production, and rapid delivery to patients. An alternative, scientifically sound aFMT replacement modality would necessitate characterization of a person-specific ''core gut mucosal microbiome function'' enabling the generation of individualized bio-active commensal probiotic consortia providing post-antibiotics mucosal protection and core microbiome function. We expect such a highly defined, individual-tailored modality to enable improved clinical efficacy and reproducibility of probiotic use while minimizing the related potential consequences of indiscriminate probiotics colonization. This ''personalized probiotics'' approach merits further research.
Our study features several important limitations. We tested, in mice and humans, a single combination of broad-spectrum antibiotics and one (albeit diverse) orally administered probiotics mixture. Other combinations of antibiotics, probiotics, and treatment routes and timings merit further studies. Furthermore, our study was conducted in healthy adults voluntarily consuming antibiotics as part of this trial and was not aimed or powered to assess clinical responses to probiotics. Results may differ in the context of disease and in extreme age groups such as the pediatric population, in which the microbiome configuration has yet to stably mature and stabilize, or the geriatric population, which features other distinct microbiome changes.
Notwithstanding these limitations, our study demonstrates, in one empiric multi-strain probiotic preparation, that the presumed probiotic-induced protection from antibiotic-associated adverse effects may not be risk-free. Like any other medical treatment, its potentially beneficial pathogen-repellant activity (which remains to be proven or refuted) may carry a tradeoff risk of adversely impacting the rate and extent of indigenous microbiome recolonization and reversion of the host gut transcriptome toward naive configuration. In contrast, new strategies, such as aFMT or person-specific microbial consortia (the latter not tested in this study), may harness individualized microbiome uniqueness in optimizing microbial colonization without adversely impacting indigenous microbiome reconstitution. Such new individualized interventions may enable achieving a more sustained live bacterial treatment efficacy upon antibiotic treatment or in a variety of other microbiome-associated medical conditions.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Clinical trial
The human MUSPIC trials were approved by the Tel Aviv Sourasky Medical Center Institutional Review Board (IRB approval numbers TLV-0553-12, TLV-0658-12 and TLV-0196-13) and Weizmann Institute of Science Bioethics and Embryonic Stem Cell Research oversight committee (IRB approval numbers 421-1, 430-1 and 444-1), and were reported to https://clinicaltrials.gov/ (Identifiers: NCT03218579 and NCT01922830). Written informed consent was obtained from all subjects.
Exclusion and inclusion criteria (human cohorts)
All subjects fulfilled the following inclusion criteria: males and females, aged 18-70, who are currently not following any diet regimen or dietitian consultation and are able to provide informed consent. Exclusion criteria included: (i) pregnancy or fertility treatments; (ii) usage of antibiotics or antifungals within three months prior to participation; (iii) consumption of probiotics in any form within one month prior to participation, (iv) chronically active inflammatory or neoplastic disease in the three years prior to enrollment; (v) chronic gastrointestinal disorder, including inflammatory bowel disease and celiac disease; (vi) active neuropsychiatric disorder; (vii) myocardial infarction or cerebrovascular accident in the six months prior to participation; (viii) coagulation disorders; (ix) chronic immunosuppressive medication usage; (x) pre-diagnosed type I or type II diabetes mellitus or treatment with anti-diabetic medication. Fulfillment of inclusion and exclusion criteria was validated by medical doctors.
Human Study Design
Forty-six healthy volunteers were recruited for this study between the years 2014 and 2018 (see Table S1 ). Upon enrollment, participants were required to fill up medical, lifestyle and food frequency questionnaires, which were reviewed by medical doctors before the acceptance to participate in the study. Two cohorts were recruited, a naive cohort (n = 25) and an antibiotics-treated cohort (n = 21), subdivided into three interventions of probiotics (n = 8), autologous fecal microbiome transplantation (aFMT, n = 6) and spontaneous reconstitution (n = 7). For the antibiotics-treated cohort, the study design consisted of four phases, baseline (7 days), antibiotics (7 days), intervention (28 days) and follow-up (28 days). During the 4-week intervention phase (days 1 through 28), participants from the probiotics arm were instructed to consume a commercial probiotic supplement (Bio-25) bi-daily; participants from the aFMT arm received an intrajejunal infusion of 150 ml of processed and liquefied stool (on day 0), which had been obtained from the participant prior to the antibiotics therapy; and participants from the spontaneous reconstitution group did not undergo any treatment. Stool samples were collected daily during the baseline and antibiotics phases, daily during the first week of intervention and then weekly throughout the rest of the intervention, bi-monthly and monthly during the follow-up phase. Participants in the antibiotics cohort underwent two endoscopic examinations, one at the end of the antibiotics phase (day 0) and another three weeks through the intervention phase (day 21). Participants in the naive cohort underwent a single endoscopic examination, of whom ten collected daily stool samples on the seven days prior to the endoscopy. All 46 subjects completed the trial as planned and there were no dropouts or withdrawals. In this trial, 10 minor adverse events were reported and fully resolved. All participants received payment for their participation in the study upon discharge from their last endoscopic session.
METHOD DETAILS
Drugs and biological preparations Antibiotics During the antibiotics phase participants were required to consume oral ciprofloxacin 500 mg (Ciprodex, Dexcel Pharma) bi-daily and oral metronidazole 500 mg (Flagyl, Sanofi) tri-daily for a period of 7 days. 
Probiotics
During the probiotics phase participants consumed Supherb Bio-25 bi-daily, which is described by the manufacturer to contain at least 25 billion active bacteria of the following species : B. bifidum, L. rhamnosus, L. lactis, L. casei subsp. casei, B. breve, S. thermophilus, B. longum subsp. longum, L. casei subsp. paracasei, L. plantarum and B. longum subsp. infantis. The pills underwent double coating to ensure their survival under stomach acidity and their proliferation in the intestines. Validation of the aforementioned species quantity and viability was performed as part of the study . Autologous fecal microbiome transplantation Participants assigned to the aFMT study arm were requested to attend the bacteriotherapy unit of the Tel Aviv Sourasky Medical Center and deposit a fresh stool sample of at least 350 gr. The sample promptly underwent embedding in glycerol, homogenization, filtering and was transferred to storage at À80 C. The sample was thawed 30 min prior to the endoscopic procedure and placed in syringes. A volume of 150 ml of the preparation was given as an intrajejunal infusion at the end of the first (post-antibiotics) endoscopic examination. The average fecal content was 70.02 ± 22.28 gr per 150 ml suspension.
Gut microbiome sampling
Stool sampling Participants were requested to self-sample their stool on pre-determined intervals (as previously described) using a swab following detailed printed instructions. Collected samples were immediately stored in a home freezer (À20 C) for no more than 7 days and transferred in a provided cooler to our facilities, where they were stored at À80
C. Endoscopic examination Forty-eight hours prior to the endoscopic examination, participants were asked to follow a pre-endoscopy diet. 20 hours prior to the examination diet was restricted to clear liquids. All participants underwent a sodium picosulfate (Pico Salax)-based bowel preparation. Participants were equipped with two fleet enemas, which they were advised to use in case of unclear stools. The examination was performed using a Pentax 90i endoscope (Pentax Medical) under light sedation with propofol-midazolam.
Luminal content was aspirated from the stomach, duodenum, jejunum, terminal ileum, cecum and descending colon into 15 ml tubes by the endoscope suction apparatus and placed immediately in liquid nitrogen. Brush cytology (US Endoscopy) was used to scrape the gut lining to obtain mucosal content from the gastric fundus, gastric antrum, duodenal bulb, jejunum, terminal ileum, cecum, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. Brushes were placed in screw cap micro tubes and were snap-frozen in liquid nitrogen. Biopsies from the gut epithelium were obtained from the stomach, duodenum, jejunum, terminal ileum, cecum, and descending colon and were snap-frozen in liquid nitrogen. By the end of each session, all samples were transferred to Weizmann Institute of Science and stored in À80 C. Mouse study design Eight-week old male C57BL/6 mice (average initial weight 20 gr) were purchased from Harlan Envigo and allowed to acclimatize to the animal facility environment for two weeks prior to the experiments. In all experiments, age-and gender-matched mice were used. All mice were kept at a strict 24 hr light-dark cycle, with lights on from 6am to 6pm. Every experimental group consisted of two cages per group to control for cage effect (n = 5 per cage). For antibiotic treatment, mice were given a combination of ciprofloxacin (0.2 g/l, Sigma-Aldrich) and metronidazole (1 g/l, LKT laboratories) in their drinking water for two weeks as previously described (Suez et al., 2014) . For probiotics supplementation, a single pill (Supherb Bio-25) was dissolved in 10 ml of sterile PBS and immediately fed to mice by oral gavage during the dark phase (4X10 9 CFU kg -1 day -1 ). For aFMT, fecal pellets were collected prior to antibiotics administration and snap-frozen in liquid nitrogen; during the day of aFMT, the pellets from each mouse were separately resuspended in sterile PBS under anaerobic conditions (Coy Laboratory Products, 75% N 2 , 20% CO 2 , 5% H 2 ), vortexed for three minutes and allowed to settle by gravity for 2 min. Samples were immediately transferred to the animal facility in Hungate anaerobic culture tubes and the supernatant was administered to the mice by oral gavage. Stool was collected on pre-determined days at the beginning of the dark phase, and immediately snap-frozen and transferred for storage at À80 C until further processing. During each time point, each group was handled by a different researcher in one biological hood to minimize cross-contamination. Upon the termination of experiments, mice were sacrificed by CO 2 asphyxiation, and laparotomy was performed by employing a vertical midline incision. After the exposure and removal of the digestive tract, it was dissected into eight parts: the stomach; beginning at the pylorus, the proximal four cm of the small intestine was collected as the duodenum; the following third of the small intestine was collected as the proximal and distal jejunum; the ileum was harvested as the distal third of the small intestine; the cecum; lastly, the colon was divided into its proximal and distal parts. For each section, the content within the cavity was extracted and collected for luminal microbiome isolation, and the remaining tissue was rinsed three times with sterile PBS and collected for mucosal microbiome isolation. A total of 710 fecal samples, 680 luminal and 680 mucosal samples were analyzed. All animal studies were approved by the Weizmann Institute of Science Institutional Animal Care and Use committee (IACUC), application number 29530816-2.
Bacterial cultures
Bacterial strains used in this study are listed in the Key Resource Table. For culturing of bacteria from the probiotics pill, the following liquid media were used: De Man, Rogosa and Sharpe (MRS), modified reinforced clostridial (RC), M17, Brain-Heart Infusion (BHI), or chopped meat carbohydrate medium (CM). All growth media were purchased from BD. Cultures were grown under anaerobic conditions (Coy Laboratory Products, 75% N 2 , 20% CO 2 , 5% H 2 ) in 37 C without shaking. For fecal microbiome cultures, $200 mg of frozen human feces was vortexed in 5 ml of BHI under anaerobic conditions. 200 ml of the supernatant were transferred to fresh 5 ml of BHI for initiation of growth. Stationary phase probiotics cultures were filtered using a 0.22 mM filter and added to the fecal culture. For pure Lactobacillus cultures, each strain was grown in liquid MRS under anaerobic conditions. Nucleic acid extraction DNA purification DNA was isolated from endoscopic samples, both luminal content and mucosal brushes, using DNeasy PowerLyzer PowerSoil Kit (QIAGEN). DNA was isolated from stool swabs using PowerMag Soil DNA Isolation Kit (QIAGEN) optimized for an automated platform.
RNA Purification
Gastrointestinal biopsies obtained from the participants were purified using RNAeasy kit (QIAGEN, 74104) according to the manufacturer's instructions. Most of the biopsies were kept in RNAlater solution (ThermoFisher, AM7020) and were snap-frozen in liquid nitrogen.
Nucleic acid processing and library preparation qPCR Protocol for Quantification of Bacterial DNA DNA templates were diluted to 1 ng per reaction before amplifications with the primer sets (indicated in Table S3 ) using the Fast Sybr Green Master Mix (ThermoFisher) in duplicates. Amplification conditions were: denaturation 95 C for three minutes, followed by 40 cycles of denaturation 95 C for 3 s; annealing 64 C for 30 s followed by meting curve. Duplicates with > 2 cycle difference were excluded from analysis. The CT value for any sample not amplified after 40 cycles was defined as 40 (threshold of detection). 16S rDNA Sequencing For 16S amplicon pyrosequencing, PCR amplification was performed spanning the V4 region using the primers 515F/806R of the 16S rRNA gene and subsequently sequenced using 2X250 bp paired-end sequencing (Illumina MiSeq). Custom primers were added to Illumina MiSeq kit resulting in 253 bp fragment sequenced following paired end joining to a depth of 110,998 ± 66,946 reads (mean ± SD).
Read1: TATGGTAATTGTGTGCCAGCMGCCGCGGTAA Read2: AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT Index sequence primer: ATTAGAWACCCBDGTAGTCCGGCTGACTGACTATTAGAA Whole genome shotgun sequencing 100 ng of purified DNA was sheared with a Covaris E220X sonicator. Illumina compatible libraries were prepared as described (Suez et al., 2014) , and sequenced on the Illumina NextSeq platform with a read length of 80bp to a depth of 6294093 ± 5732308 (stool) or 3366309 ± 4950053 (lumen and mucosa) reads (mean ± SD). RNA-Seq Ribosomal RNA was selectively depleted by RnaseH (New England Biolabs, M0297) according to a modified version of a published method (Adiconis et al., 2013) . Specifically, a pool of 50 bp DNA oligos (25 nM, IDT, indicated in Table S4 ) that is complementary to murine rRNA18S and 28S, was resuspended in 75 ml of 10 mM Tris pH 8.0. Total RNA (100-1000 ng in 10 ml H 2 O) were mixed with an equal amount of rRNA oligo pool, diluted to 2 ml and 3 ml 5x rRNA hybridization buffer (0.5 M Tris-HCl, 1 M NaCl, titrated with HCl to pH 7.4) was added. Samples were incubated at 95 C for 2 min, then the temperature was slowly decreased (À0.1 C/s) to 37 C. RNaseH enzyme mix (2 ml of 10 U RNaseH, 2 mL 10x RNaseH buffer, 1 mL H 2 O, total 5 ml mix) was prepared 5 min before the end of the hybridization and preheated to 37 C. The enzyme mix was added to the samples when they reached 37 C and they were incubated at this temperature for 30 min. Samples were purified with 2.2x SPRI beads (Ampure XP, Beckmann Coulter) according to the manufacturers' instructions. Residual oligos were removed with DNase treatment (ThermoFisher Scientific, AM2238) by incubation with 5ml DNase reaction mix (1 ml Trubo DNase, 2.5ml Turbo DNase 10x buffer, 1.5 ml H 2 O) that was incubated at 37 C for 30 min. Samples were again purified with 2.2x SPRI beads and suspended in 3.6 ml priming mix (0.3 ml random primers of New England Biolab, E7420, 3.3 ml H 2 O). Samples were subsequently primed at 65 C for 5 min. Samples were then transferred to ice and 2 ml of the first strand mix was added (1 ml 5x first strand buffer, NEB E7420; 0.125 ml RNase inhibitor, NEB E7420; 0.25 ml ProtoScript II reverse transcriptase, NEB E7420; and 0.625 ml of 0.2 mg/ ml Actinomycin D, Sigma, A1410). The first strand synthesis and all subsequent library preparation steps were performed using NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB, E7420) according to the manufacturers' instructions (all reaction volumes reduced to a quarter). 16S rDNA analysis The 2X250 bp reads were processed using the QIIME (Caporaso et al., 2010) (Quantitative Insights Into Microbial Ecology, http:// www.qiime.org) analysis pipeline. In brief, FASTA quality files and a mapping file indicating the barcode sequence corresponding to each sample were used as inputs. Paired reads were first assembled into longer reads based on sequence similarity, and then split to samples according to the barcodes. Sequences sharing > 97% nucleotide sequence identity in the 16S rRNA region were binned into operational taxonomic units (97% ID OTUs). Each OTU was assigned a taxonomical classification by applying the Uclust algorithm against the Greengenes database, and an OTU table was created. Metagenomic analysis Data from the sequencer was converted to fastq files with bcl2fastq. Reads were then QC trimmed using Trimmomatic (Bolger et al., 2014) with parameters PE -threads 10 -phred33 -validatePairs ILLUMINACLIP:TruSeq3-PE.fa:2:30:10 LEADING:3 TRAILING:3 MINLEN:50. We used MetaPhlAn2 (Truong et al., 2015) for taxonomic analysis with the parameters: -ignore_viruses -ignore_archaea -ignore_eukaryotes.
Host sequences were removed by aligning the reads against human genome reference hg19 using bowtie2 (Langmead and Salzberg, 2012 ) with the parameters: -D 5 -R 1 -N 0 -L 22 -i S,0,2.50. The resulting non-host reads were then mapped to the integrated gene catalog (Qin et al., 2010) using bowtie2 with parameters:-local -D 25 -R 3 -N 1 -L 19 -i S,1,0.25 -k 5 allowing to a single read to match up to five different entries.
Further filtering of the bacterial reads consisted of retaining only records with minimal base quality of 26. The resulting bacterial quality-filtered bam files were then subsampled to 1X10 5 and 5X10 5 bacterial hits for endoscopic and stool samples, respectively.
6. Determining probiotic strain presence in each sample. We characterized the presence of strain genes that were expected to be covered by at least one read for each percent of all genes covered by one or more reads using simulations. Based on the simulations we designed functions that bound 95% and 99% of the simulated results using R functions loess.SD and approxfun. Assignment of probiotic strains to species was done according to the following key: 'Unknown', < 20% of all genes were covered by at least one read; 'Do not contain the probiotic strain', the fraction of strain specific genes were below the 99% function; 'Possibly contain the probiotic strain', samples in which the fraction of strain genes was between the 95% to the 99% functions; 'Contain the probiotic strain', the fraction of strain genes was above the 95% function.
RNA-seq analysis
Reads were trimmed using cutadapt (Martin, 2011) and mapped to hg38 Homo sapiens genome using STAR (Dobin et al., 2013) v2.4.2a (default parameters) . Genes were annotated using RefSeq. Genes having a minimum of 5 reads in at least one sample were considered for further analysis. Normalization of the counts and differential expression analysis was performed using DESeq2 (Love et al., 2014) 
QUANTIFICATION AND STATISTICAL ANALYSIS
The following statistical analyses were applied unless specifically stated otherwise: for 16S data, rare OTUs (< 0.1% in relative abundance) were filtered out, and samples were then rarefied to a depth of 10,000 reads. For metagenomic data, samples with < 1X10 5 (endoscopic samples) or < 5X10 5 (stool samples) assigned bacterial reads (after host removal) were excluded from further analysis. In the remaining samples, rare KEGG orthologous (KO) genes (< 0.1%) were removed. Beta diversity was calculated on OTUs (16S) or species (metagenomics) relative abundances using UniFrac distances or Bray-Curtis dissimilarity (R Vegan package, https:// cran.r-project.org/web/packages/vegan/index.html), respectively. Beta diversity for KOs and functional bacterial pathways was calculated using Spearman's rank correlation coefficient. Alpha diversity was calculated on OTUs (16S) using the observed species index. For 16S data, measurements of alpha and beta diversity were calculated using QIIME tools v 1.9.1. In order to determine the effect of treatment on microbiota taxonomic composition and functional capacity repeated-measures Kruskal Wallis with Dunn's test was used. In order to compare the effect of treatment over time between two groups or more Two-Way ANOVA with Dunnet's test, or permutation tests performed by switching labels between participants (in a paired fashion when suitable), including all their assigned samples, were used. Mann-Whitney and Wilcoxon tests were used to conduct pairwise comparisons between two treatment arms or two groups of participants. Permutational multivariate ANOVA (Adonis PERMANOVA with 10,000 permutations) based on sample distances was used to test for changes in the community composition and function. To analyze qPCR data, Two way ANOVA with Sidak or Dunnett test was used. The threshold of significance was determined to be 0.05 both for p and q-values. Statistically significant findings were marked according to the following cutoffs: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Data were plotted with GraphPad Prism version 7.0c. Statistical details for all experiments, including sample size, the statistical test used, dispersion and precision measures and statistical significance, are specified in the result section and denoted in figure legends. 
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